5-α-reductase inhibitor Dutasteride, Finasteride, AR antagonist Flutamide, Bicalutamide and ER blocker Toremifene are investigated as chemoprevention agents for prostate cancer in clinical trials [2, 3, 13–17]. Here, ESR1 is linked to prostate cancer.